Trial · NCT00602446
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
NCT00602446, Phase 2, Terminated, Masonic Cancer Center, University of Minnesota; results first posted 2010-03-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant. Trials, record NCT00602446. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00602446
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
- NCT number
- NCT00602446
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
- Interventions
- deferasirox
- First posted
- 2008-01-28
- Last updated
- 2017-12-28
- Results first posted
- 2010-03-30
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients Not Completing Treatment | 6 Months | Number of patients who discontinued deferasirox during 6 month daily treatment due to drug related toxicity |
| Secondary | Reduction in Liver Iron Concentration After Study Drug | 6 Months | Efficacy as measured by reduction in liver iron concentration (LIC) after 6 months of the study drug compared to baseline (LIC at baseline minus LIC at 6 months). This shows the mean reduction for the 3 subjects treated in this study. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients Not Completing Treatment | 6 Months | Note: 1 patient had a transient decrease in hemoglobin that required discontinuation of treatment for 2 weeks; subsequently restarted at same dose and completed therapy. | Participants | NUMBER |
| SECONDARY | Reduction in Liver Iron Concentration After Study Drug | 6 Months | All patients included in count. | milligrams/gram | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Not Completing Treatment | Deferasirox Treated | 0 | Participants | ||
| Reduction in Liver Iron Concentration After Study Drug | Deferasirox Treated | 5.6 | Standard Deviation 4.8 | milligrams/gram |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Deferasirox Treated | 3 | |
| Overall Study | COMPLETED | Deferasirox Treated | 3 | |
| Overall Study | NOT COMPLETED | Deferasirox Treated | 0 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash | Skin and subcutaneous tissue disorders | Deferasirox Treated | 2 | 3 | 2 |
| other | Diarrhea | Gastrointestinal disorders | Deferasirox Treated | 3 | 3 | 3 |
| other | Increased serum creatinine | Blood and lymphatic system disorders | Deferasirox Treated | 2 | 3 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Deferasirox Treated | ||
| Total, other adverse events | Deferasirox Treated | 3 | 3 |
| Total, serious adverse events | Deferasirox Treated | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00602446
GET https://conductscience.org/api/trials/v1/NCT00602446/registered